Table 1.
Comparison with previous case reports of VKH disease after vaccination for COVID-19.
| Study | Age/sex | Type of vaccine | Dose | Time to onset of visual symptoms | Type of VKH disease | Pretreatment BCVA (OD, OS) | Final BCVA (OD, OS) | Route of administration of systemic corticosteroid therapy |
|---|---|---|---|---|---|---|---|---|
| Reddy Y et al. | 30/F | AZD1222 | 1st | 7 days | SRD | CF, CF | 6/9, 6/9 | Oral |
| Kim SY et al. | 72/F | AZD1222 | 1st | 3 days | ODS | 20/40, 20/40 | 20/20, 20/20 | Intravenous for 3 days followed by oral |
| Brunet de Courssou JB et al. | 57/F | BNT162b2 | 1st | 5 weeks | SRD | 20/60, 20/80 | 20/20, 20/20 | Intravenous for 3 days followed by oral |
| Saraceno JJF et al. | 62/F | AZD1222 | 1st | 4 days | SRD | 20/600, 20/200 | 20/20, 20/20 | Oral |
| Koong LR et al. | 54/M | BNT162b2 | 1st | 4 days | SRD | 6/24, 6/45 | 6/12, 6/12 | Intravenous for 3 days followed by oral |
| Current | 30s/F | BNT162b2 | 2nd | 2 weeks | SRD | 20/50, 20/70 | 20/20, 20/20 | Intravenous for 3 days followed by oral |
VKH = Vogt-Koyanagi-Harada, BCVA = best-corrected visual acuity, SRD = serous retinal detachment, ODS = optic disc swelling, CF = counting fingers, HM = hand motion.